The U.S. Food and Drug Administration (FDA) has approved Nulojix (belatacept) for prevention of acute rejection in adult patients who have had a kidney transplant. Read more.
FDA approves Nulojix for prevention of acute rejection in kidney transplant patients
The views and opinions expressed here are those of the author and do not necessarily reflect the opinions or recommendations of the American Nurses Association, the Editorial Advisory Board members, or the Publisher, Editors and staff of American Nurse Journal. This has not been peer reviewed.